证券代码：002424 证券简称：ST百灵 公告编号：2024-064 贵州百灵企业集团制药股份有限公司 关于第六届监事会第八次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、监事会召开情况 议案一、审议通过《2024年第三季度报告》。 经审核，监事会认为：董事会编制和审核《2024年第三季度报 告》的程序符合法律、行政法规和中国证监会的规定，报告内容真 实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届监事会第八次会议由公司监事会主席周春刚先生召集，会议通知 于2024年10月15日以专人送达、电子邮件、电话等通讯方式发出。 2、本次监事会于 2024 年 10 月 25 日下午 2:00 在公司三楼会议 室以现场表决方式召开。 3、本次监事会应到监事5人，实到5人。 4、本次监事会由监事会主席周春刚先生主持，公司高级管理人 员列席了本次会议。 5、本次监事会的召集、召开符合《公司法》《公司章程》《监 事会议事规则》及相关法规的规定，会议 ...

Financial Performance - The company's total revenue for Q1 2023 was ¥1,091,626,153.16, Q2 was ¥807,905,305.20, Q3 was ¥910,203,782.87, and Q4 was ¥1,453,236,198.98[3] - The net profit attributable to shareholders for Q1 2023 was ¥92,306,394.78, Q2 was ¥120,338,248.40, Q3 was ¥20,142,383.96, and Q4 showed a loss of ¥647,298,248.31[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q1 2023 was ¥88,450,072.54, Q2 was ¥117,444,988.05, Q3 was ¥16,887,476.14, and Q4 was a loss of ¥649,298,489.64[3] - The net cash flow from operating activities for Q1 2023 was -¥57,871,366.46, Q2 was ¥121,367,095.84, Q3 was -¥75,862,188.38, and Q4 was ¥138,133,517.47[3] Data Accuracy and Transparency - The company acknowledged errors in the quarterly financial data reported in the 2023 annual report and has committed to improving the quality of information disclosure[2] - The company expressed apologies for the inconvenience caused to investors due to the data correction in the annual report[7] - The company plans to enhance the review process for information disclosure documents to prevent similar issues in the future[7] - The corrected financial data will not affect the overall financial condition and operating results for the year 2023[6] - The company will impose penalties on responsible personnel for the errors in the annual report data submission[7] - The company aims to maintain transparency and accuracy in its financial reporting moving forward[2]

证券代码：002424 证券简称：ST 百灵 公告编号：2024-060 类型：股份有限公司（上市、自然人投资或控股） 住所：贵州省安顺市经济技术开发区西航路 212 号 贵州百灵企业集团制药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）于 2024 年 4 月 16 日、2024 年 5 月 6 日分别召开第六届董事 会第八次会议及 2024 年第二次临时股东大会，审议通过了《关于变 更回购股份用途并注销的议案》《关于修订<公司章程>的议案》，同意 对已回购的部分股份的用途进行变更，回购股份用途由"用于员工持 股计划或者股权激励"变更为"用于注销并相应减少注册资本"，即 对回购专用证券账户中部分股份 13,601,600 股进行注销并相应减少 注册资本，同意公司增加经营范围，并对《公司章程》部分内容进行 修订。上述具体内容详见公司于 2024 年 4 月 17 日、2024 年 5 月 7 日在《证券时报》《证券日报》《中国证券报》和巨 ...

4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项，股票异常 波动期间，公司控股股东、实际控制人未买卖公司股票； 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）股票（证券简称：ST 百灵，证券代码：002424）连续 2 个交 易日（2024 年 9 月 30 日、2024 年 10 月 8 日）日收盘价格累计偏离 -14.40%，根据深圳证券交易所的有关规定，属于股票交易异常波动 的情况。 二、公司关注及核实情况说明 1、公司未发现前期披露的信息存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格 产生较大影响的未公开重大信息； 证券代码：002424 证券简称：ST 百灵 公告编号：2024-061 3、公司目前的经营情况及内外部经营环境未发生重大变化； 特此公告。 5、公司不存在导致股票交易严重异常波动的未披露事项。 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-059 贵州百灵企业集团制药股份有限公司 关于公司董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）董事 会于近日收到公司总经理、董事、董事会秘书牛民先生递交的书面辞 职报告。牛民先生因个人原因申请辞去公司董事会秘书职务，辞去上 述职务后，将继续担任公司总经理、董事及董事会委员会委员职务。 根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法律法规、规范性指引及《公司章程》的 有关规定，牛民先生的辞职报告自送达董事会之日起生效。 截至本公告披露日，牛民先生持有公司 270,600 股股份，占公司 总股本的 0.02%，除此之外未通过其他方式持有公司股份。 牛民先生辞去公司董事会秘书职务，不会影响公司董事会正常运 作，不会影响公司正常生产经营。牛民先生在担任公司董事会秘书期 间勤勉尽责、恪尽职守。公司及董事会对牛民先生在担任董事会秘书 期间为公司作出的贡献表示衷心的感谢。 为保证公司董事 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-058 贵州百灵企业集团制药股份有限公司 关于控股股东部分股份办理质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 3、最近一年又一期控股股东姜伟先生不存在非经营性资金占用、 违规担保等侵害上市公司利益的情形。 公司控股股东姜伟先生质押股份数量为 245,346,161 股，累计占 其所持公司股份数量比例 100%，请投资者注意相关风险。 近日，贵州百灵企业集团制药股份有限公司（以下简称"本公 司"） 接到控股股东姜伟先生函告，获悉姜伟先生近日将已质押给海 通证券股份有限公司的部分股票办理股票质押式回购交易延期购回， 具体事项如下： 股东 名称 是否为 控股股 东或第 一大股 东及其 一致行 动人 本次质押数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 为补 充质 押 质押起始 日 质押到期 日 延期购 回后到 期日 质权 人 质押用 途 姜伟 是 12,875,998 5.25% 0.92% 否 否 2017 年 8 月 22 日 ...

| 表 | | --- | | 债 | | 负 | | 产 | | 奖 | | 井 | | 4 I | | 编制单位:贵州百灵企业集团制药股份有限公司 | | | | | | | 会合01表 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 单位:人民币元 | | | | | 上年年末数 | 负债和所有者权益 (或股东权益) | 注释 름 | 期末数 | 上年年末数 | | 流动资产: | | | | | | | | | 货币资金 | | | 417, 938, 537. 62 | 流动负债: | | | | | 结算备付金 | | | | 短期借款 | 23 | 1, 460, 265, 191. 73 | 1, 436, 017, 612. 52 | | | | | | 向中央银行借款 | | | | | 拆出资金 | | | | 拆入资金 | | | | | 父易性金融资 | | | | 父易性金融负债 | | | | | 衍生金融资产 | | | | 衍生金融负债 | | | | | 应收票据 | 2 | 13, 3 ...

证券代码：002424 证券简称：ST百灵 公告编号：2024-055 贵州百灵企业集团制药股份有限公司 关于第六届监事会第七次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、监事会召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届监事会第七次会议由公司监事会主席周春刚先生召集，会议通知 于2024年8月16日以专人送达、电子邮件、电话等通讯方式发出。 2、本次监事会于 2024 年 8 月 27 日下午 2:00 在公司三楼会议室 以现场表决方式召开。 3、本次监事会应到监事5人，实到5人。 三、备查文件 1、经与会监事签字并加盖监事会印章的监事会决议； 4、本次监事会由监事会主席周春刚先生主持，公司高级管理人 员列席了本次会议。 5、本次监事会的召集、召开符合《公司法》、《公司章程》、 《监事会议事规则》及相关法规的规定，会议召开合法有效。 二、监事会会议审议情况 本次会议经过充分讨论，会议审议通过了以下议案： 议案一、审议通过《2024年半年度报告及摘要》。 经审核，监事会认为：董事会编制和审核《2024年半 ...

Financial Performance - Guizhou Bailing reported no cash dividends or stock bonuses for the 2024 fiscal year[1]. - The company's operating revenue for the first half of 2024 was CNY 2,142,835,969.60, representing a 12.81% increase compared to CNY 1,899,531,458.36 in the same period last year[11]. - Net profit attributable to shareholders decreased by 27.32% to CNY 87,461,409.09 from CNY 120,338,248.40 year-on-year[11]. - The net profit from non-recurring gains and losses dropped by 72.28% to CNY 32,563,183.46 compared to CNY 117,463,745.33 in the previous year[11]. - The net cash flow from operating activities was negative at CNY -30,370,447.37, a decline of 125.02% from CNY 121,367,095.84 in the same period last year[11]. - The total assets at the end of the reporting period were CNY 7,487,694,865.06, an increase of 1.89% from CNY 7,349,081,335.53 at the end of the previous year[11]. - The weighted average return on equity decreased to 2.50% from 3.01% year-on-year[11]. - The company reported a basic and diluted earnings per share of CNY 0.06, down 33.33% from CNY 0.09 in the previous year[11]. - The company received government subsidies amounting to CNY 34,161,420.51 during the reporting period[13]. - The company’s net profit for the first half of 2024 was CNY 162,316,204.81, compared to CNY 140,662,883.66 in the first half of 2023, indicating a growth of 15.4%[111]. Business Strategy and Development - The report emphasizes the importance of risk awareness for investors regarding future plans and strategies[1]. - The management discussion section highlights the company's strategies for addressing risks and challenges[1]. - The company continues to focus on the development of new products and technologies[1]. - The company is focusing on the development of new extraction technologies and quality control methods to enhance the efficacy and safety of traditional Chinese medicine[16]. - The company aims to strengthen its leading position in the苗药 field and become a core competitive enterprise in the中成药 sector[22]. - The company is actively expanding its market presence and enhancing its production capabilities through the establishment of a large-scale manufacturing platform and a comprehensive marketing platform[22]. - The company is focusing on technological innovation and increasing investment in R&D to enhance its product offerings and market competitiveness[22]. - The company is committed to addressing the growing healthcare needs driven by an aging population and increasing health awareness among consumers[18]. - The company is enhancing its compliance with regulatory requirements, which is expected to support its sustainable development[17]. Research and Development - The company submitted 25 new Chinese medicine drug applications by June 2024, with a year-on-year increase of 150% in submissions[16]. - The company has established various R&D platforms, including a national-level joint engineering research center and a postdoctoral research station, to enhance its core competitiveness in drug development[30]. - The company has a total of 85 valid patents, including 54 domestic invention patents, 14 design patents, and 17 utility model patents[29]. - The company's R&D investment decreased by 46.31% to CNY 26,197,053.74 from CNY 48,795,249.56 in the previous year, influenced by the varying stages of R&D projects[34]. - The company is focusing on improving research and development management to address risks associated with drug development cycles and uncertainties[55]. Market and Sales - The company has a diverse product portfolio, including key products such as银丹心脑通软胶囊, 咳速停糖浆, and 小儿柴桂退热颗粒, which hold significant market shares in their respective categories[19][20]. - The revenue from traditional Chinese medicine products amounted to CNY 2,020,485,196.9, accounting for 94.29% of total revenue, with a year-on-year growth of 16.61%[37]. - The commercial segment saw a significant revenue increase of 46.10%, with a gross profit margin of 59.98%, reflecting a 6.55% improvement in cost management[36]. - The company has established a marketing network covering over 32 provinces, cities, and autonomous regions, with more than 600,000 terminal customers and over 100,000 signed VIP customers[33]. - The company has expanded its marketing efforts to include grassroots medical institutions, successfully developing over 100,000 such institutions[33]. Financial Management and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management[1]. - The company plans to enhance its financial management and internal control systems to ensure compliance and effective decision-making[25]. - The company is committed to improving compliance with securities laws and regulations following a warning from the regulatory authority[76]. - The company’s board and management are taking measures to enhance internal controls and prevent operational risks[73]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[132]. Environmental and Social Responsibility - The company has established a dedicated environmental protection department to oversee compliance with environmental regulations and standards[62]. - The company has implemented a comprehensive environmental management system and emergency response plans for environmental incidents[62]. - The company has achieved a daily wastewater treatment capacity of 5,000 tons with the completion of the second phase of its wastewater treatment and reuse project, which is set to be operational soon[68]. - The company actively participates in social welfare activities, supporting local education, culture, and health initiatives, and has built traditional Chinese medicine planting bases in impoverished areas[68]. - The company has received national-level honors such as "Green Factory" and "Water-saving Enterprise," reflecting its commitment to environmental protection and sustainable practices[67]. Shareholder and Corporate Governance - The company held two temporary shareholder meetings and one annual shareholder meeting in 2024, with investor participation rates of 0.49%, 0.58%, and 1.36% respectively[58][59]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[59]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[100]. - The company completed a share buyback of 20,491,812 shares, accounting for 1.47% of the total share capital, with a total transaction amount of RMB 119,587,599.20[95]. - The largest shareholder, Jiang Wei, holds 17.39% of the shares, totaling 245,346,284 shares, with 61,336,571 shares pledged[97]. Regulatory and Legal Matters - The company failed to disclose performance forecasts within the required timeframe after the end of the 2023 fiscal year, violating regulations[76]. - The company has not engaged in any significant related party transactions during the reporting period[77]. - There were no major litigation or arbitration matters during the reporting period[75]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[74]. - The company has not provided any non-operating fund occupation by controlling shareholders or related parties during the reporting period[70]. Accounting and Financial Reporting - The financial statements have been approved by the board of directors on August 27, 2024, reflecting the company's financial status and operating results[130]. - The company adheres to the accounting standards for enterprises, ensuring the financial statements are true and complete[134]. - The company has implemented new accounting policies effective January 1, 2024, including the classification of current and non-current liabilities, with no impact on financial statements[198]. - The company recognizes revenue when the customer obtains control of the goods or services, typically at the point of delivery, and is measured based on the transaction price allocated to each performance obligation[188]. - The company assesses the carrying value of expected liabilities and adjusts them based on the best estimate of the required expenditures[187].

证券代码：002424 证券简称：ST 百灵 公告编号：2024-054 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十一次会议决议的公告 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《2024年半年度报告及摘要》。 关于《2024年半年度报告》及《2024年半年度报告摘要》详见公 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、会议召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届董事会第十一次会议由公司董事长姜伟先生召集，会议通知于 2024 年 8 月 16 日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于 2024 年 8 月 27 日上午 10:00 在公司三楼会议 室以现场结合通讯方式召开。 3、本次董事会应参会表决董事共 9 人，实际参会表决的董事 9 人。其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 5、本次董事会的召集、召开符合《公司法》、《公司章程》、《董事 会议事规则》及相关 ...